Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Dulaglutide (Trulicity) vs Tirzepatide
An educational, source-based comparison of Dulaglutide (Trulicity) and Tirzepatide — how each peptide works, what it's researched for, and what to know before going deeper.
Once-weekly GLP-1 agonist with cardiovascular benefit.
GLP-1 analog fused to a modified human IgG4 Fc fragment, giving a half-life that supports weekly dosing. Improves glycemia and reduces MACE in T2D.
- Type 2 diabetes
- Cardiovascular risk reduction in T2D
- • FDA-approved.
- • Boxed warning: thyroid C-cell tumors in rodents.
A dual agonist of the GLP-1 and GIP receptors. The combined incretin action improves glucose control and produces greater weight loss than GLP-1 monotherapy in head-to-head trials.
- Type 2 diabetes (Mounjaro)
- Chronic weight management (Zepbound)
- Sleep apnea in obesity (recent approval)
- • FDA-approved; requires prescription and physician oversight.
- • GI side effects are dose-limiting.
- • Compounded versions are not FDA-evaluated.
Dulaglutide (Trulicity) vs Tirzepatide — Key differences
- Class: Dulaglutide (Trulicity) is classified as GLP-1 Agonist · Metabolic, while Tirzepatide is Metabolic · Incretin.
- Primary research focus: Dulaglutide (Trulicity) — type 2 diabetes; Tirzepatide — type 2 diabetes (mounjaro).
- Tag: FDA-Approved · Metabolic vs Weight loss.